CA-SCIENTIST.COM
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i® , the company’s new supplier pre-assessment program, has officially launched with the successful completion of an on-site assessment of Boca Biolistics’s biorepository facilities. VERIF.i was developed to help both sides of the Scientist.com marketplace. Pre-assessments help suppliers such as Boca Biolistics demonstrate their quality and capabilities, while helping pharma and biotech customers select regulated services in an accelerated manner with more confidence and less risk.
“We have always been confident in the quality of our facilities and the personnel that operate them,” stated Joseph Mauro, Chief Vision Officer at Boca Biolistics. “VERIF.i allows us to demonstrate our expertise to current and future clients of Scientist.com’s marketplace as well as to our existing clientele outside of the platform."
Boca Biolistics is a hybrid contract research organization (CRO) with an integrated life science biorepository, offering central laboratory testing as well as clinical trial services. The company procures human biospecimens from around the world for commercial product development and the advancement of precision medicine. VERIF.i enables Boca Biolistics and other suppliers of regulated research services to communicate their standards against pre-defined criteria developed for the biopharma industry and then confirm them through independent, third-party auditors that carry out an on-site inspection.
“On-site assessments are expensive, resource intensive and time consuming for customers and suppliers,” stated Matt McLoughlin, Sr. VP of Categories and Compliance at Scientist.com. “VERIF.i standardizes and simplifies the process for both sides of the market. It enables suppliers to differentiate themselves from their peers while enabling customers to gain valuable, unbiased insight into a supplier’s facilities, personnel and processes."
VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/
About Boca Biolistics
Boca Biolistics is a hybrid CRO leveraging our vertically integrated model to build a life sciences biorepository with industry leading clinical and molecular data sets. Our commercial biobank has >800,000 specimens available for use in R&D as well as clinical trials. Our CLIA/CAP accredited reference lab offers clinical testing as well as research testing services for diagnostic and pharma. Our CRO division provides end-to-end services for both diagnostic and biopharma clinical trials.
Visit bocabio.com to learn more.
Join us on our LinkedIn page.
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005020/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively19.9.2025 12:00:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL,biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919502394/en/ “The EC approvals of BILDYOS and BILPREVDA mark a pivotal moment in expanding access to essential bone care treatments for millions of Europeans, particularly women, who are disproportionately affected by osteoporosis,” said Nico Van Hoecke, Head, International Commercial at Organon.3,4 “These biosimilars may offer additional treatment options across several therapeutic areas associated with bone loss, including osteoporosis, and reflect Organon’s commitment to advancing women’s health through access to im
Cluster Reply Supports Riverty’s AI-first Strategy for Omnichannel,Human-centric Customer Service19.9.2025 11:15:00 CEST | Press release
Cluster Reply, the Reply company specialised in digital platform solutions leveraging Microsoft technologies, has partnered with fintech company Riverty to accelerate the rollout of a pioneering customer service platform – delivered in record time of just 100 days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919101836/en/ The initiative is part of Riverty’s broader strategy to become a leader in AI-powered financial services. The new solution empowers Riverty to deliver efficient, empathetic customer support across all channels while creating a robust foundation for future AI-driven automation. The initiative is part of Riverty’s broader strategy to become a leader in AI-powered financial services. The new solution empowers Riverty to deliver efficient, empathetic customer support across all channels while creating a robust foundation for future AI-driven automation. The platform leverages Microsoft Dynamics 365 Custom
L&T Technology Services Joins the MIT Media Lab to Collaborate on AI-led Innovations19.9.2025 10:30:00 CEST | Press release
With access to world-class research and breakthrough problem-solving opportunities, LTTS will explore next-gen technologies in Mobility, Sustainability and Tech L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a multi-year membership agreement with the MIT Media Lab, one of the world’s most prestigious research institutions. As a consortium Lab Member, LTTS intends to explore next-generation advancements in artificial intelligence (AI), underscoring its commitment to driving transformational innovation in Mobility, Sustainability and Tech. As part of the agreement, LTTS will engage in active discussions and information exchange with the Media Lab’s unique cross-disciplinary ecosystem that brings together researchers, innovators and industry leaders. The collaboration not only emphasizes practical AI innovation but also accelerates technology-driven advancements by linking LTTS’ expertise in AI and engineering w
SMBC Group and Jefferies Significantly Expand Their Global Strategic Alliance19.9.2025 10:00:00 CEST | Press release
Joint Venture to Combine Equities and ECM Businesses in JapanExpanding Joint Coverage of Larger SponsorsIn EMEA, Implementing Joint Origination, Underwriting and Execution of Syndicated Leveraged Finance for These ClientsSMBC to Increase Equity Ownership in Jefferies to up to 20% in the Open MarketSMBC to Provide Jefferies Approximately $2.5 Billion in New Credit Facilities to Support Jefferies and to Facilitate Collaboration Efforts Jefferies Financial Group, Inc. (NYSE: JEF) (“Jefferies”) and Sumitomo Mitsui Financial Group, Inc. (NYSE: SMFG) (“SMFG”), Sumitomo Mitsui Banking Corporation (“SMBC”), and SMBC Nikko Securities Inc. (“SMBC Nikko”) (collectively, “SMBC Group”) announced today that they are significantly expanding their Global Strategic Alliance. SMBC Group and Jefferies initially entered into a Strategic Alliance in 2021 to collaborate on future corporate and investment banking business opportunities. In 2023, the Alliance was expanded to enhance collaboration across M&A,
REJO MULTI Unveiled at InterTabac 2025, Featuring Dual-Heating and Cross-Brand Compatibility19.9.2025 10:00:00 CEST | Press release
Flexible brand options, enhanced aroma, and reduced tobacco consumption empower REJO's ambition in Europe REJO, a global heat-not-burn (HNB) pioneer, officially unveiled REJO MULTI device at InterTabac 2025 as one of the exhibition’s most anticipated products. The device introduces a dual-heating system that pairs AirFlow and Round Heating technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919713971/en/ REJO MULTI Product Launch Event “REJO MULTI represents a major step forward in HNB technology,” said Loic Li, the Global Sales Director of REJO. “Its open compatibility allows users to explore multiple brands and flavors with a single device, while our dual-heating system ensures even heating, enhanced aroma delivery, and consistent nicotine satisfaction.” “Our goal with REJO MULTI is to empower users with choice and flexibility, while providing retailers and partners with an innovative, market-ready product that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom